ALXO Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own ALXO shares is 141, representing 94.67% of the company's common stock.

BLACKROCK INC., in the last quarter, reduced its stake in ALXO by -0.61% restricting it's holding to 2.22 million shares of worth nearly $24.77M. MORGAN STANLEY also lessened -17.08% of the ALXO shares from its portfolio, reducing its holding to 343.14 thousand shares of worth $3.83M. MARTINGALE ASSET MANAGEMENT L P also shunned ALXO shares holding by -14.04% last quarter which brought its holding to 36.2 thousand shares worth $403.58K.

As per its latest 13F filing, SQUAREPOINT OPS LLC increased its stake in ALXO by 100% in the last quarter. The institutional holder raised its holding to 106.36 thousand shares having worth more than $1.19M. MARSHALL WACE, LLP also added 950.62% more shares of ALXO to its portfolio, raising its holding to 121.55 thousand shares of worth $1.36M. WELLINGTON MANAGEMENT GROUP LLP also increased its ALXO shares holding by 57.44% which brought its holding to 127.04 thousand shares worth $1.42M.

The insider with the most stakes in ALXO is Pons Jaume , PRESIDENT & CSO at the company. Additionally, ALXO stock is highly held by CHIEF MEDICAL OFFICER Randolph Sophia and 10 percent owner LSV Associates, LLC among others.

Company executives, directors, and other insiders own 1.97% percent of ALX Oncology Holdings Inc.'s stock. Within the last six months, there have been 6 transaction(s) in which ALXO insiders have sold stock, totaling 18.31K shares. Insiders that have sold shares include PINTO SHELLY, PONS JAUME, and RANDOLPH SOPHIA.

There have been 1 transaction(s) during the past 6-months in which ALX Oncology Holdings Inc. insiders have bought stock, totalling 30000 shares

Around 1.8M ALX Oncology Holdings Inc. shares are held by insiders, which represents about 1.97% of ALXO stock.

ALXO PRESIDENT & CSO, Pons Jaume holds the largest portfolio of the company's shares. ALXO shares owned by Pons total nearly 580.71 thousand.

SQUAREPOINT OPS LLC is the largest institutional owner in ALXO which holds 106.36 thousand shares worth $1.19M or 0.25% of the total ALXO shares outstanding followed by MARSHALL WACE, LLP with ownership of 121.55 thousand shares representing 0.28% of the ALXO ownership. WELLINGTON MANAGEMENT GROUP LLP is the third largest stakeholder with 127.04 thousand shares or 0.3% of the ownership worth more than $1.42M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the ALXO is concerned, it is a stock which is optionable.

Number of ALXO shares short is 7.83M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 52.74M shares of ALXO are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, ALXO has 27.14M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for ALXO is 6.81.